In vitro susceptibility to amphotericin B, itraconazole, voriconazole, posaconazole and caspofungin of Aspergillus spp. isolated from patients with haematological malignancies in Tunisia

被引:24
|
作者
Gheith, Soukeina [1 ,2 ,3 ]
Saghrouni, Fatma [2 ]
Bannour, Wadiaa [1 ]
Ben Youssef, Yosra [4 ]
Khelif, Abderrahim [4 ]
Normand, Anne-Cecile [5 ,6 ]
Piarroux, Renaud [5 ,6 ]
Ben Said, Moncef [2 ]
Njah, Mansour [1 ,2 ]
Ranque, Stephane [5 ,6 ]
机构
[1] CHU Farhat Hached, Serv Hyg Hosp, Sousse 4000, Tunisia
[2] Minist Sante Publ, Unite Rech UR 04SP24, Tunis, Tunisia
[3] CHU Farhat Hached, Lab Parasitol Mycol, Sousse 4000, Tunisia
[4] CHU Farhat Hached, Serv Hematol Clin, Sousse, Tunisia
[5] CHU Timone Adultes, Assistance Publ Hop Marseille, Parasitol & Mycol, F-13005 Marseille, France
[6] Aix Marseille Univ, IP TPT UMR MD3, F-13885 Marseille, France
来源
SPRINGERPLUS | 2014年 / 3卷
关键词
Invasive aspergillosis; Haematological malignancies; Aspergillus; In vitro susceptibility; Antifungal drugs; Amphotericin B; Itraconazole; Voriconazole; Posaconazole; Caspofungin; Paradoxical growth; Trailing effect; MIC; In vitro susceptibility testing; EPIDEMIOLOGIC CUTOFF VALUES; MIC DISTRIBUTIONS; RESISTANCE; INFECTIONS; FUMIGATUS; FLAVUS;
D O I
10.1186/2193-1801-3-19
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The resistance of Aspergillus species to antifungal is increasingly reported and the knowledge of the local epidemiology and antifungal susceptibility pattern is pivotal to define adequate treatment policies. Our study aimed to: 1) describe the in vitro antifungal susceptibility profile of the Aspergillus species isolated from patients with haematological malignancies in Tunisia; 2) compare the E-test and Sensititre Yeast-One assays for the detection of paradoxical growth and trailing effect, both phenotypes commonly exhibited by Aspergillus spp. upon exposure to caspofungin and 3) to evaluate the mortality rate in patients according to the causative Aspergillus species and the antifungal treatment. We tested amphotericin B, itraconazole, voriconazole, posaconazole and caspofungin against 48 Aspergillus isolates (17, A. niger; 18, A. flavus; 9, A. tubingensis; 1, A. westerdijkiae; and 1, A. ochraceus) with the E-test. Minimal inhibition concentrations were above the epidemiological cut-off values for amphotericin B in 67% of A. flavus strains; for caspofungin in 22% of A. flavus strains; and for itraconazole in 22% of A. tubingensis strains, voriconazole and posaconazole MICs were below the epidemiological cut-off values for all strains. When exposed to caspofungin, 42% of the strains exhibited trailing effect and 38% paradoxical growth. Trailing effect occurred in 61% of A. flavus strains and paradoxical growth in 62% of Aspergillus section Nigri strains. E-test and Sensititre Yeast-One assays were only fairly concordant for the detection of these phenotypes. Repeatability of both assays was high for trailing effect but poor for paradoxical growth. The relatively high frequency of amphotericin B resistant strains makes voriconazole best adapted as a first-line treatment of invasive aspergillosis from amphotericin B to voriconazole in this hospital.
引用
收藏
页数:8
相关论文
共 50 条
  • [2] In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin
    Shi Jun-yan
    Xu Ying-chun
    Shi Yi
    Lue Huo-xiang
    Liu Yong
    Zhao Wang-sheng
    Chen Dong-mei
    Xi Li-yan
    Zhou Xin
    Wang He
    Guo Li-na
    CHINESE MEDICAL JOURNAL, 2010, 123 (19) : 2706 - 2709
  • [3] In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole
    Kaya, Ayse Demet
    Kiraz, Nuri
    MYCOSES, 2007, 50 (06) : 447 - 450
  • [4] In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole
    Dannaoui, E
    Persat, F
    Monier, MF
    Borel, E
    Piens, MA
    Picot, S
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (04) : 553 - 555
  • [5] In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
    Lewis, RE
    Wiederhold, NP
    Klepser, ME
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) : 945 - 951
  • [6] In-vitro activity of voriconazole against Aspergillus spp. And comparison with itraconazole and amphotericin B
    Oakley, KL
    Moore, CB
    Denning, DW
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (01) : 91 - 94
  • [7] In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusatium spp.
    Philip, A
    Odabasi, Z
    Rodriguez, J
    Paetznick, VL
    Chen, E
    Rex, JH
    Ostrosky-Zeichner, L
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) : 3572 - 3574
  • [8] Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole
    Espinel-Ingroff, A
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) : 605 - 607
  • [9] Sensitivity of filamentous fungi isolated from fungal keratitis to amphotericin B, natamycin, caspofungin, itraconazole, voriconazole, and posaconazole
    Shapiro, BL
    Lalitha, P
    Fothergill, AW
    Ruiz, J
    Srinivasan, M
    Prajna, NV
    Pan, Y
    McLeod, S
    Lietman, TM
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
  • [10] Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus
    Manavathu, EK
    Abraham, OC
    Chandrasekar, PH
    CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 (03) : 130 - 137